What Is Selank?
Selank is a synthetic analog of tuftsin, a tetrapeptide (Thr-Lys-Pro-Arg) that occurs naturally in the human body as a cleavage product of the Fc region of immunoglobulin G (IgG). Tuftsin was first identified in the 1970s and is primarily known for its role in innate immunity. It enhances the phagocytic activity of macrophages and neutrophils. However, tuftsin itself proved impractical as a therapeutic agent due to rapid enzymatic degradation, with a plasma half-life measured in seconds.
In the 1990s, a research team led by Nikolai Myasoedov at the Institute of Molecular Genetics of the Russian Academy of Sciences, in collaboration with the V.V. Zakusov Research Institute of Pharmacology, set out to create a metabolically stable version of tuftsin that could serve as a therapeutic agent for anxiety disorders. By appending the tripeptide sequence Pro-Gly-Pro to tuftsin's C-terminus, they created Selank, a heptapeptide that retained tuftsin's immunomodulatory properties while gaining pronounced neurotropic effects and substantially improved resistance to enzymatic degradation.
Selank was approved by the Russian Federation Ministry of Health in 2009 and is available by prescription in Russia under the brand name Selanc, and is also reportedly available in Ukraine. It is marketed as a 0.15% nasal spray solution for the treatment of generalized anxiety disorder (GAD) and as an adjunctive treatment for neurasthenic conditions. In Russian clinical practice, it has been prescribed since the early 2010s, typically in 14-day treatment courses.
The compound's dual heritage, rooted in both immunology (tuftsin) and neuropsychopharmacology, gives it a pharmacological profile that is unusual among anxiolytics. It is neither a classical benzodiazepine nor a selective serotonin reuptake inhibitor, but a peptide that modulates multiple neurotransmitter systems simultaneously while preserving immune function.
How It Works
Selank's mechanism of action is multifaceted, involving at least four distinct neurochemical and immunological pathways. This polypharmacology likely explains both its broad therapeutic profile and its favorable side effect profile. Rather than saturating a single receptor system, Selank modulates several systems at moderate intensity.
GABAergic and Serotonergic Modulation
The most extensively studied mechanism of Selank involves its interaction with the GABAergic system. Research published in Frontiers in Pharmacology demonstrated that Selank administration rapidly alters the expression of genes involved in GABAergic neurotransmission, including genes encoding GABA-A receptor subunits. The peptide appears to allosterically modulate GABA-A receptors in a manner pharmacologically similar to benzodiazepines, enhancing inhibitory neurotransmission to reduce anxiety, but without directly binding the benzodiazepine site.
This distinction is critical. Classical benzodiazepines (diazepam, alprazolam, phenazepam) bind directly to a specific allosteric site on the GABA-A receptor, producing potent anxiolysis alongside sedation, muscle relaxation, cognitive impairment, tolerance development, and physical dependence. Selank's indirect modulation of the GABAergic system appears to produce anxiolysis without these accompanying effects. In a clinical comparison with phenazepam, Selank achieved comparable anxiety reduction without sedation, muscle relaxation, tolerance, or withdrawal syndrome.
Selank also modulates serotonergic pathways. In murine models where serotonin synthesis was experimentally reduced, Selank administration modulated serotonin metabolism in brainstem regions critical for mood regulation. This dual GABAergic-serotonergic activity may account for Selank's antidepressant effects observed alongside its primary anxiolytic action.
BDNF and Neuroplasticity
Brain-derived neurotrophic factor (BDNF) is a protein essential for neuronal survival, synaptic plasticity, and the formation of new neural connections. Reduced BDNF expression is implicated in depression, anxiety disorders, and cognitive decline. Experimental data from rodent models demonstrate that Selank increases BDNF mRNA expression in the hippocampus, a brain region central to memory processing and emotional regulation.
This BDNF upregulation is particularly significant under stress conditions. Chronic stress and elevated glucocorticoids suppress hippocampal BDNF expression, contributing to the cognitive impairment and emotional dysregulation seen in anxiety disorders. Selank's ability to counteract this stress-induced BDNF suppression provides a mechanistic explanation for its nootropic effects, improved memory, enhanced learning, and greater cognitive flexibility under pressure.
The neuroplasticity effects also have temporal implications. While Selank's GABAergic modulation produces rapid anxiolysis (within minutes of intranasal administration), BDNF-mediated neuroplastic changes develop over days to weeks of treatment, potentially explaining the progressive cognitive improvements observed during 14-day treatment courses.
Enkephalin System Effects
Enkephalins are endogenous opioid peptides that play central roles in mood regulation, stress response, and pain modulation. In patients with generalized anxiety disorder, research has documented decreased levels of leu-enkephalin, with the deficit correlating with disease duration and symptom severity.
Selank inhibits the enzymatic degradation of enkephalins by suppressing the activity of enkephalin-degrading enzymes. This prolongs the half-life and increases the availability of endogenous enkephalins, effectively boosting the body's own stress-buffering opioid system without introducing exogenous opioids. In the clinical trial comparing Selank to medazepam, Selank treatment produced measurable increases in leu-enkephalin levels that correlated with improvements in anxiety scores, a finding not observed with the benzodiazepine comparator.
This mechanism is distinct from and complementary to Selank's GABAergic effects. While GABA-A modulation provides rapid anxiolysis, enkephalin stabilization addresses the underlying neurochemical deficit associated with chronic anxiety, potentially contributing to more durable therapeutic effects.
Immune Modulation
Selank retains and extends the immunomodulatory properties of its parent peptide tuftsin. Research examining 84 inflammation-related genes found that Selank significantly altered the expression of 34 genes across functional groups including chemokines, chemokine receptors, cytokines, and cytokine receptors.
Key immunological findings include:
- Interferon-alpha induction: Selank administration induces expression of the IFN-alpha gene without affecting IL-4, IL-10, or TNF-alpha expression. This selective interferon induction suggests antiviral activity without broad inflammatory activation.
- IL-6 modulation: Selank influences interleukin-6 expression, a cytokine involved in both immune defense and neuroinflammation. The direction and magnitude of this effect appear context-dependent, potentially reflecting an immunomodulatory rather than immunostimulatory role.
- Phagocytic enhancement: Consistent with its tuftsin heritage, Selank enhances the phagocytic activity of monocytes and neutrophils, supporting innate immune surveillance.
- Th1/Th2 balance: Selank appears to influence the balance between Th1 and Th2 cytokine profiles, with implications for immune regulation in both infectious and autoimmune contexts.
This immune dimension distinguishes Selank from virtually all conventional anxiolytics, which either have no effect on immune function or suppress it. For individuals whose anxiety coexists with immune compromise or chronic infection, Selank's dual neurotropic-immunomodulatory profile is pharmacologically unique. For dedicated immune peptides, see Thymosin Alpha 1.